Skip to content
Screener

Operating Income at other companies

Amgen logo
AmgenAMGN
$3.51B+32.3%
Vera Therapeutics logo
Vera TherapeuticsVERA
-$125.13M-119%
PVL
Palvella TherapeuticsPVLA
-$14.86M-88.7%
Regenxbio logo
RegenxbioRGNX
$29.26M+146%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$16.78M+124%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
-$15.55M-8.0%

Other financials

Income statement

See full
Revenue$284.0K+279%
Net income-$127.1M-26.2%
EPS (diluted)-$1.15-5.5%

Balance sheet

See full
Cash & equivalents$165.0M+40.6%
Total debt$114.4M+395%
Total equity$662.1M+28.5%
Total assets$1.1B+88.4%

Cash flow

See full
Operating cash flow-$105.3M-39.7%
CapEx$1.3M+3,010%
Free cash flow-$106.6M-41.4%

Valuation

See full
Market cap$2.55B+81.7%
Enterprise value$2.5B+90.9%
P/S35.9×-4,565×

Profitability

See full
Gross margin36.3%
Operating margin-569.7%-284pp
Net margin-544.1%-271pp
FCF margin-471%-235pp

Returns & leverage

See full
Return on equity-65.7%-0.1pp
Debt / equity0.2×+0.1×
Current ratio16.9×+5.9×

Where this comes from

Reported directly by Viridian Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:31 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001590750-26-000018
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Research and development (1)71,57786,626149,208163,461
Selling, general and administrative54,97520,21693,65437,319
Total operating expenses126,552106,842242,862200,780
Loss from operations(126,268)(106,767)(242,437)(200,633)
Other income (expense), net:
Interest income8,4906,54616,36214,086
Interest expense(8,307)(514)(11,769)(1,100)
Change in fair value of derivative liability(1,190)6,340

Item 1. Financial Statements (Unaudited)

FAQ

What is Viridian Therapeutics, Inc.'s operating income?
Viridian Therapeutics, Inc. (VRDN) reported operating income of -$126.27M in Q2 2026.
How has Viridian Therapeutics, Inc.'s operating income changed year-over-year?
Viridian Therapeutics, Inc.'s operating income decreased by 18.3% year-over-year, from -$106.77M to -$126.27M.
What is the long-term trend for Viridian Therapeutics, Inc.'s operating income?
Over 4 years (2021 to 2025), Viridian Therapeutics, Inc.'s operating income has grown at a 46.1% compound annual growth rate (CAGR), from -$79.73M to -$363.4M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Viridian Therapeutics, Inc.'s operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude